Therapeutic modulation of transcription factor activity

Trends in Pharmacological Sciences

Volumn 22, Issue 5, 2001, Pages 233-240

  Emery, John G ^a   Ohlstein, Eliot H ^a   Jaye, Michael ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; NEW DRUG; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REGULATOR; UNCLASSIFIED DRUG;

DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSCRIPTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; TRANSCRIPTION FACTORS;

EID: 0035339220     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01661-8     Document Type: Review

References (72)

1. TRANSFAC: An integrated system for gene expression regulation
2. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
3. Sterol regulatory element-binding proteins (SREBPs): Key regulators of nutritional homeostasis and insulin action
4. Hairpin orientation of sterol regulatory element-binding protein-2 in cell membranes as determined by protease protection
5. Transport-dependent proteolysis of SREBP: Relocation of site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi
6. Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells
7. Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs
8. Four cholesterol-sensing proteins
9. Transcriptional regulation of adipogenesis
10. MAP kinases erk1/2 phosphorylate sterol regulatory element-binding protein (SREBP)-1a at serine 117 in vitro
11. Nuclear hormone receptor coregulators in action: Diversity for shared tasks
12. Orphan nuclear receptors: Shifting endocrinology into reverse
13. The RXR heterodimers and orphan receptors
14. Increasing the complexity of coactivation in nuclear receptor signaling
15. Transcriptional repression by nuclear hormone receptors
16. Basic guide to the mechanisms of antiestrogen action
17. Nuclear receptor ligand-binding domains: Three-dimensional structures, molecular interactions and pharmacological implications
18. Molecular basis of agonism and antagonism in the oestrogen receptor
19. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
20. Comparative analyses of mechanistic differences among antiestrogens
21. An issue of tissues: Divining the split personalities of selective estrogen receptor modulators
22. Molecular mechanism of a cross-talk between oestrogen and growth factor signaling pathways
23. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
24. Regulation of lipid and lipoprotein metabolism by PPAR activators
25. Peroxisome proliferator-activated receptors: Insight into multiple cellular functions
26. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation
27. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus - A randomized controlled trial
28. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight
29. Nuclear receptors in metabolic diseases
30. Activation of PPAR δ alters lipid metabolism in db/db mice
31. PPAR δ functions as a prostacyclin receptor in blastocyst implantation
32. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
33. Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects
34. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
35. The homeodomain resource: Sequences, structures and genomic information
36. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1
37. The homeodomain protein IDX-1: A master regulator of pancreas development and insulin expression
38. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia
39. The nuclear localization signal (NLS) of PDX-1 is part of the homeodomain and represents a novel type of NLS
40. Identification of a nuclear localization signal, RRMKWKK, in the homeodomain transcription factor PDX-1
41. Glucose stimulates translocation of the homeodomain transcription factor PDX1 from the cytoplasm to the nucleus in pancreatic beta-cells
42. Possible involvement of atypical protein kinase C (PKC) in glucose-sensitive expression of the human insulin gene: DNA-binding activity and transcriptional activity of pancreatic and duodenal homeobox gene-1 (PDX-1) are enhanced via calphostin C-sensitive but phorbol 12-myristate 13-acetate (PMA) and Go 6976-insensitive pathway
43. Glucagon-like peptide-1 regulates the β cell transcription factor, PDX-1, in insulinoma cells
44. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells
45. Transforming growth factor beta induction of insulin gene expression is mediated by pancreatic and duodenal homeobox gene-1 in rat insulinoma cells
46. Insulin stimulates pancreatic-duodenal homeobox factor-1 (PDX1) DNA-binding activity and insulin promoter activity in pancreatic β cells
47. Histone deacetylase (HDAC) mediates Smad6 repressive functioning BMP signalling pathway
48. A homogeneous high-throughput binding assay for studying the interactions between Hoxc-8 and Smad1 in BMP-induced signal transduction
49. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
50. Transcription factors of the NFAT family: Regulation and function
51. 2+, calcineurin, and NF-AT
52. 2+ signals and immunosuppression
53. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3
54. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1
55. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway
56. Identification of amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization
57. Manipulating immune responses with immunosuppressive agents that target NFAT
58. FK506, an immunosuppressant targeting calcineurin function
59. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A
60. NF-κB: Ten years after
61. The NF-κB and IκB proteins: New discoveries and insights
62. Structure, regulation and function of NF-κB
63. The IκB kinase (IKK) and NF-κB: Key elements of proinflammatory signalling
64. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase
65. IKK1-deficient mice exhibit abnormal development of skin and skeleton
66. Limb and skin abnormalities in mice lacking IKKα
67. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase
68. IKKε is part of a novel PMA-inducible IκB kinase complex
69. Sulindac inhibits activation of the NF-κB pathway
70. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
71. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-κB activation, IκBα phosphorylation, and degradation
72. Evaluation of the effectiveness of DNA-binding drugs to inhibit transcription using the c-fos serum response element as a target